PIO laser SPNP: PIO Laser Sclerectomy IOP SLT Sclerectomy

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Completed
CT.gov ID
NCT01798732
Collaborator
(none)
26
1
1
39
0.7

Study Details

Study Description

Brief Summary

The main objective of this study is to characterize the changes in IOP over 24 hours after selective trabeculoplasty SLT (before and 1 and 6 months after treatment, decreased IOP, type of rhythm, mesor, acrophase, amplitude). The secondary objective is to evaluate changes in ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after selective laser trabeculoplasty.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Selective Laser Trabeculoplasty on the Intraocular Pressure Nycthemeral Rhythm.
Study Start Date :
Aug 1, 2011
Actual Primary Completion Date :
Nov 1, 2014
Actual Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Selective laser trabeculoplasty (Tango Laser, Ellex)

Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)

Procedure: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)

Outcome Measures

Primary Outcome Measures

  1. IOP change over 24 hours after selective trabeculoplasty SLT according to chronobiological data (decrease of IOP; type of 24h-IOP rhythm and 24h-PPm rhythm: MESOR, acrophase, bathyphase, amplitude and modeling) [Baseline and 6 months]

Secondary Outcome Measures

  1. Changes in the rate of ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after SLT. [Baseline and 6 months]

    To find predictive factors 1 month before efficacy of the treatment (after 6 month). Efficacy is defined by a mean IOP decrease, at least 30%, with a smoothed pressure-peaks (decrease at least 40% of pressure changes) To characterize changes of ocular blood flow parameters (optic nerve head; Volume, Velocity and Flow): 20% at least of increase.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Primary Open-Angle Glaucoma

  • IOP more than 21 mmHg

  • Progression under maximal medical therapy

  • aged more than 18 years

Exclusion Criteria:
  • Pregnant woman

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Grenoble Grenoble France

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

  • Principal Investigator: Jean-Paul ROMANET, Pr, University Hospital, Grenoble

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT01798732
Other Study ID Numbers:
  • 1012
  • 2010-A00932-37
First Posted:
Feb 26, 2013
Last Update Posted:
Nov 17, 2014
Last Verified:
Nov 1, 2014
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 17, 2014